Lite Strategy, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Lite Strategy, Inc. (LITS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $6.92 per share for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-19.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-09-19
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-09-30 was $7.01, a 1198.15% increase year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-09-30 was $0.54, a 81.57% decline year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-09-30 was $2.93, a 15.32% decline year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-09-30 was $3.46, a 38.40% increase year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.92, a 28.14% decline from fiscal 2023.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $9.63, a 274.71% increase from fiscal 2022.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.57, a 24.19% decline from fiscal 2021.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $3.39, a 35.60% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-06-30 | $6.92 10-K · filed 2024-09-19 | |||||
| 2023-12-31 | $6.92 10-Q · filed 2024-05-09 | $6.90 10-Q · filed 2024-02-13 | ||||
| 2023-09-30 | $7.01 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | $9.63 10-K · filed 2023-09-26 | |||||
| 2023-03-31 | $10.66 10-Q · filed 2023-05-11 | |||||
| 2022-12-31 | $0.53 10-Q · filed 2023-02-09 | |||||
| 2022-09-30 | $0.54 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $2.57 10-K · filed 2022-09-08 | |||||
| 2022-03-31 | $2.71 10-Q · filed 2022-05-23 | |||||
| 2021-12-31 | $2.93 10-Q/A · filed 2022-05-23 | |||||
| 2021-09-30 | $2.93 10-Q/A · filed 2022-05-23 | |||||
| 2021-06-30 | $3.39 10-K/A · filed 2022-05-23 | |||||
| 2021-03-31 | $3.40 10-Q · filed 2021-05-06 | |||||
| 2020-12-31 | $3.38 10-Q · filed 2021-02-04 | |||||
| 2020-09-30 | $3.46 10-Q · filed 2020-11-10 | |||||
| 2020-06-30 | $2.50 10-K · filed 2020-09-09 | |||||
| 2020-03-31 | $2.45 10-Q · filed 2020-05-07 | |||||
| 2019-12-31 | $2.46 10-Q · filed 2020-02-06 | |||||
| 2019-09-30 | $2.50 10-Q · filed 2019-11-07 | |||||
| 2019-06-30 | $3.90 10-K · filed 2019-08-28 | |||||
| 2019-03-31 | $4.07 10-Q · filed 2019-05-09 | |||||
| 2018-12-31 | $4.18 10-Q · filed 2019-02-07 | |||||
| 2018-09-30 | $4.27 10-Q · filed 2018-11-08 | |||||
| 2018-06-30 | $3.14 10-K · filed 2018-08-30 | |||||
| 2018-03-31 | $2.72 10-Q · filed 2018-05-09 | |||||
| 2017-12-31 | $2.82 10-Q · filed 2018-02-08 | |||||
| 2017-09-30 | $2.84 10-Q · filed 2017-11-08 | |||||
| 2017-06-30 | $1.41 10-K · filed 2017-09-05 | |||||
| 2017-03-31 | $1.37 10-Q · filed 2017-05-04 | |||||
| 2016-12-31 | $1.37 10-Q · filed 2017-02-08 | |||||
| 2016-09-30 | $1.37 10-Q · filed 2016-11-09 | |||||
| 2016-06-30 | $1.59 10-K · filed 2016-09-06 | |||||
| 2016-03-31 | $1.59 10-Q · filed 2016-05-05 | |||||
| 2015-12-31 | $1.63 10-Q · filed 2016-02-05 | |||||
| 2015-09-30 | $1.62 10-Q · filed 2015-11-06 | |||||
| 2015-06-30 | $6.12 10-K · filed 2015-09-02 | |||||
| 2015-03-31 | $6.37 10-Q · filed 2015-05-07 | |||||
| 2014-12-31 | $6.66 10-Q · filed 2015-02-06 | |||||
| 2014-09-30 | $6.52 10-Q · filed 2014-11-06 | |||||
| 2014-06-30 | $7.97 10-K · filed 2014-09-09 | |||||
| 2014-03-31 | $7.58 10-Q · filed 2014-05-08 | |||||
| 2013-12-31 | $7.43 10-Q · filed 2014-02-11 | |||||
| 2013-09-30 | $7.39 10-Q · filed 2013-11-08 | |||||
| 2013-06-30 | $7.27 10-K · filed 2013-09-18 | |||||
| 2013-03-31 | $7.06 10-Q · filed 2013-05-09 | |||||
| 2012-12-31 | $4.98 10-Q · filed 2013-02-12 | |||||
| 2012-09-30 | $0.51 10-Q · filed 2012-11-13 | |||||
| 2012-06-30 | $9.78 10-K · filed 2013-09-18 | $1.63 10-K · filed 2012-09-18 | ||||
| 2011-06-30 | $1.12 10-K · filed 2012-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |